RADIATION
68Ga-NODAGA-exendin-4 PET/CT
68Ga-NODAGA-exendin-4 PET/CT
A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass
Status
Unknown
Phase
Phase 2
Enrollment
30
Locations
2
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The goal of the trial is to measure pancreatic uptake of 68Ga-NODAGA-exendin by PET/CT for detection of intra-individual differences in beta cell mass before and after treatment with Verapamil.
Full detailed description
The VER-A-T1D (Verapamil SR in adults with Type 1 Diabetes) study is an intervention study within the INNODIA project (an Innovative Medicines Initiative consortium (IMI-2), established through Horizon 2020 initiative of the European Union, involving academic, industry and charitable partners). In the VER-A-T1D study, the effects of treatment of newly diagnosed patients with T1D with Verapamil will be evaluated. Verapamil appears to protect beta cell function, an effect that could in part be caused by protection against beta cell apoptosis. GLP-1 receptors are expressed in high densities in beta cells. Exendin, a GLP-1 receptor agonist, can be labeled with radionuclides and thus be utilized for visualization of beta cells in vivo by positron emission tomography (PET). This technology has been demonstrated to deliver quantitative information of the radiotracer uptake in the pancreas demonstrating a linear correlation with beta cell mass. In VER-A-T1D, we propose to measure beta cell mass at the time points of inclusion and at evaluation after 12 months. If verapamil protects beta cells against apoptosis, we expect that the uptake of the radiotracer will be higher at 12 months in comparison to the first measurement in the treatment group. The study will be a substudy to VER-A-T1D.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Nov 4, 2020
Study start
Jul 1, 2021
Primary completion
Apr 1, 2025
Study completion
Jul 1, 2025
Results posted
Not reported
Registry updated
Dec 8, 2023
Outcomes
What the study measures.
Primary outcomes
Pancreatic 68Ga-exendin uptake
Time frame · Change from time of inclusion to 12 months into treatment
the total pancreatic uptake of 68Ga-NODAGA-exendin by PET/CT for determination of beta cell mass
Secondary outcomes
Correlation of 68Ga-exendin uptake and C-peptide
Time frame · 12 months into treatment
• Changes in 68Ga-NODAGA-exendin pancreas uptake in realtion to changes in C-peptide measurements.
relative 68Ga-exendin uptake
Time frame · 12 months into treatment
• Differences in 68Ga-NODAGA-exendin uptake between individuals and between the two timepoints of imaging intra-individually
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * • Have given written informed consent * • Age ≥18 and \<45 at consent * • Must have a diagnosis of T1D of within 6 weeks duration at screening (date of the first insulin * injection) * • Must have at least one or more diabetes-related autoantibodies present at screening * • Must have random C-peptide levels ≥200 pmol/L measured at screening * • Be willing to comply with intensive diabetes management Exclusion Criteria: * Treatment with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl-Peptidase IV inhibitors (to exclude interferences with imaging, specifically mentioned although in principle part of exclusion criteria of VER-A-T1D) * Renal disease defined as MDRD \<40 ml/min/1.73 m2 * Pregnancy or the wish to become pregnant within 2 months after the second PET/CT scan.
Study locations
2 registered sites.
Austria · France. Showing up to 24 locations stored in the fast local snapshot.
University of Vienna
Vienna, Austria
Assistance Publique hopitaux de Paris
Paris, France
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Exenatide.
NCT IDStudyPhase / statusEnrollmentUpdated
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Johns Hopkins University · Multiple Sclerosis
Phase 2
Recruiting
120
2026-07
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
AstraZeneca · Pancreatic Cancer
Not applicable
Recruiting
24,000
2026-06
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
Chinese University of Hong Kong · Cerebral Small Vessel Disease
Phase 2
Recruiting
110
2026-06
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
University Hospital, Bordeaux · Craniopharyngiomas · Hypothalamic Obesity
Phase 3
Completed
42
2026-05
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Brigham and Women's Hospital · Cardiovascular Events · Type2 Diabetes
Not applicable
Active, not recruiting
781,430
2026-05
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics
Assistance Publique Hopitaux De Marseille · Obesity · Diabetes
Phase 3
Completed
44
2026-05
Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease
University College, London · Parkinson's Disease
Phase 3
Completed
194
2026-05
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.